Myocardial Regeneration and Angiogenesis in Myocardial Infarction With G-CSF and Intra-Coronary Stem Cell Infusion

• Status: Terminated
• Trial end date: 2005-02-01
• Target enrollment: 0
• Participant gender: All

Summary

This trial was performed to evaluate the safety and the efficacy of G-CSF based stem cell therapy in patients with AMI. MAGIC Cell-1 trial enrolled patients with acute and old myocardial infarction, and had two groups of cell infusion, and G-CSF alone. MAGIC Cell-2 trial enrolled patients with acute myocardial infarction presented within 12 hours after onset of chest pain who underwent successful primary PCI. We randomized patients into the G-CSF group and the control group.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Seoul National University Hospital
• Treatments: Lenograstim

Criteria

Inclusion Criteria:

• MAGIC Cell-1 trial enrolled patients with acute and old myocardial infarction

• MAGIC Cell-2 trial enrolled patients with acute myocardial infarction presented within 12 hours after onset of chest pain who underwent successful primary PCI.

Exclusion Criteria:

• Persistent severe heart failure (above Killip class II or LVEF < 25 %)

• Uncontrolled myocardial ischemia or ventricular tachycardia

• Culprit lesion of infarct related artery not feasible for PCI or unsuccessful PCI

• Age > 75 years

• Malignancy

• Serious current infection or hematologic disease

• Life expectancy under one year.